Security key
75382E109
RAPT Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RAPT)
CUSIP: 75382E109
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 1,341,050
- Total 13F value
- $10,728,400
- Share change
- -129,765,896
- SEC-reported price per share
- $8.00
- Number of holders
- 2
- Value change
- -$158,903,455
- Number of sells
- 86
- Shares outstanding
- 27,725,634
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
2
Top holders
2
RAPT full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
RAPT Therapeutics, Inc. SEC filings
RAPT Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 75382E109
Recent filing periods:
Ownership snapshot
Top reported holders of RAPT - RAPT Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Medicxi IV LP
Disclosed value leader
COLUMN GROUP II, LP
Comparable rows
15/15
Latest evidence
30 Jun 2025
13D/G
13F
3/4/5
Lead comparable stake: 17%
13D/G row: Medicxi IV LP
Showing 1-6 of 15 holder rows.
Quick read
Medicxi IV LP leads the comparable SEC ownership view at 17%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Medicxi IV LP's linked filing trail.
Comparable ownership
Top 5
Medicxi IV LP
17%
TCG Crossover GP II, LLC
10%
Redmile Group, LLC
9.9%
Deep Track Capital, LP
9.9%
Foresite Capital Fund VI LP
9.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Medicxi IV LP |
13D/G
Medicxi IV GP Limited
|
17%
|
$19,446,240
22,352,000 shares
|
$0 | 27 Dec 2024 |
| TCG Crossover GP II, LLC |
13D/G
|
10%
|
$11,478,006
13,193,110 shares
|
$0 | 27 Dec 2024 |
| Redmile Group, LLC |
13D/G
13F
Company
|
9.9%
|
$14,934,463
1,765,303 shares
|
$0 | 30 Jun 2025 |
| Deep Track Capital, LP |
13D/G
13F
Company
|
9.9%
|
$12,280,920
14,116,000 shares
|
$0 | 23 Dec 2024 |
| Foresite Capital Fund VI LP |
13D/G
Foresite Capital Fund VI, L.P.
|
9.3%
|
$10,875,000
12,500,000 shares
|
$0 | 23 Dec 2024 |
| VANGUARD GROUP INC |
13F
13D/G
Company · The Vanguard Group
|
6.3%
from 13D/G
|
$10,100,133
8,278,798 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
2
Shares
1,341,050
Rows available
2
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q4 2025 Across Filers
Q4 2025 holders
3
Q2 2025 holders
2
Holder diff
-1
| Investor | Q4 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q4 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend